Evofem Biosciences to Participate in Four Upcoming Investor Conferences

Rhea-AI Summary

Evofem Biosciences (NASDAQ: EVFM) announced its participation in four healthcare equity conferences in September 2020. The events include:

• H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 14
• 2020 Cantor Global Virtual Healthcare Conference on September 16
• Morgan Stanley 18th Annual Global Healthcare Conference on September 18
• Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22

Webcasts will be available on the company's website. Evofem focuses on women's reproductive health and offers the hormone-free contraception product Phexxi™.

SAN DIEGO, Aug. 31, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a commercial-stage biopharmaceutical company, today announced it will participate in four healthcare equity conferences in September:

• H.C. Wainwright & Co. 22nd Annual Global Investment Conference: presentation on
  Monday, September 14, 2020 from 3:30 to 3:50 p.m. EST. 
• 2020 Cantor Global Virtual Healthcare Conference: virtual fireside chat on
  Wednesday, September 16, 2020 from 4:00 p.m. to 4:30 p.m. EST.
• Morgan Stanley 18th Annual Global Healthcare Conference: virtual fireside chat on
  Friday, September 18, 2020 from 11:00 a.m. to 11:30 a.m. EST.
• Oppenheimer Fall Healthcare Life Sciences & MedTech Summit: virtual fireside chat on
  Tuesday, September 22, 2020 from 10:50 a.m. to 11:30 a.m. EST.

To access the live and archived webcasts of these presentations, visit the Investors section of the Evofem Biosciences website at www.evofem.com, and select the Events and Presentations tab. 

About Evofem Biosciences, Inc. 
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi™ (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is also advancing EVO100 into Phase 3 clinical trials for the prevention of urogenital transmission of both Chlamydia trachomatis infection (chlamydia) and Neisseria gonorrhoeae infection (gonorrhea) in women. For more information, please visit www.evofem.com.

Phexxi™ is a trademark of Evofem Biosciences, Inc.

Investor Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
M: (917) 673-5775

Media Contact
Becky Vonsiatsky
W2O Group
bvonsiatsky@w2ogroup.com 
M: (413) 478-2003

View original content to download multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-participate-in-four-upcoming-investor-conferences-301120737.html

SOURCE Evofem Biosciences, Inc.

FAQ

What conferences is Evofem Biosciences participating in September 2020?

Evofem Biosciences is participating in the H.C. Wainwright & Co. Annual Global Investment Conference, Cantor Global Virtual Healthcare Conference, Morgan Stanley Global Healthcare Conference, and Oppenheimer Fall Healthcare Summit.

When is the H.C. Wainwright Conference for Evofem?

The H.C. Wainwright & Co. conference is on September 14, 2020, from 3:30 to 3:50 p.m. EST.

What is the focus of Evofem Biosciences?

Evofem Biosciences focuses on developing innovative products for women's sexual and reproductive health.

What is Phexxi™ by Evofem Biosciences?

Phexxi™ is a hormone-free, prescription vaginal gel approved to prevent pregnancy.

Where can I find the webcasts for Evofem's presentations?

The webcasts for Evofem's presentations can be accessed on their website under the Events and Presentations section.